BofA update shows where active managers are putting money
Investing.com - Guggenheim has raised its price target on Eli Lilly (NYSE:LLY) to $942.00 from $936.00 while maintaining a Buy rating ahead of the company’s second-quarter earnings report. The pharmaceutical giant, currently valued at over $709 billion, has shown remarkable strength with a 36% revenue growth in the last twelve months. According to InvestingPro analysis, analyst targets for LLY range from $650 to $1,190, reflecting diverse views on the stock’s potential.
The research firm estimates second-quarter Mounjaro sales of $4.49 billion compared to consensus estimates of $4.39 billion from VisibleAlpha and $4.89 billion from FactSet. This includes projected U.S. sales of $3.00 billion versus VisibleAlpha’s consensus of $3.19 billion.
For Zepbound, Guggenheim forecasts second-quarter U.S. sales of $3.10 billion, slightly above the consensus estimate of $2.94 billion. The firm noted a significant discrepancy currently exists between FactSet and VisibleAlpha consensus numbers for Mounjaro.
Guggenheim’s updated model includes revised tirzepatide forecasts based on prescription analysis and incorporates an estimated $0.14 impact on earnings per share from second-quarter IPR&D (in-process research and development).
The firm highlighted that investors are focused on tirzepatide prescription and net price trends, along with several pivotal clinical trial readouts expected through the remainder of 2025, including Phase 3 ATTAIN-1 results for orforglipron in obesity in the third quarter and the first Phase 3 readout for retatrutide in the fourth quarter.
In other recent news, Eli Lilly has received FDA approval for a new dosing schedule of its Alzheimer’s drug, Kisunla. The updated regimen is designed to significantly reduce the incidence of amyloid-related imaging abnormalities while maintaining effective amyloid plaque reduction. Meanwhile, JPMorgan has reiterated its Overweight rating on Eli Lilly, forecasting strong second-quarter sales driven by products like Mounjaro and Zepbound. UBS also maintained a buy rating, highlighting the company’s leadership in the obesity treatment market and anticipating quarterly sales to surpass consensus expectations. Eli Lilly’s acquisition of Verve Therapeutics for up to $1.3 billion has led BMO Capital to downgrade Verve Therapeutics, reflecting the strategic importance of this acquisition for Eli Lilly. Evercore ISI maintained its In Line rating on Eli Lilly following clinical trial results for bimagrumab, noting positive weight loss outcomes but also some safety concerns. These developments underscore Eli Lilly’s active role in advancing its pharmaceutical portfolio and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.